ACT-MBC: A Study of Circulating Tumor Cells (CTCs) in Metastatic Breast Cancer (MBC)
Active, not recruiting · NCT05662345
Conditions: Metastatic Breast Cancer
At a glance
- Research payments reported, 2025
- $585,052
- U.S. investigators named
- 2
- Sites paid
- 2
- Planned or actual enrollment
- 65
About the trial
- Sponsor
- Menarini Silicon Biosystems, INC (with Medex15)
- Tested
- CellSearch Circulating Tumor Cells (diagnostic_test)
- Dates
- Started 2022-12-12; completion 2026-10
- Results posted
- Not yet
ACT-MBC prospectively assesses the impact of CTCs on treatment decisions, response assessment and prognosis in MBC patients.
From ClinicalTrials.gov, last updated 2026-03-17. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Menarini Silicon Biosystems, Inc. reported $585,052 in research payments for this study in 2025 (104 payments).
Products named: Cellsearch
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Carl Landgren, MD Hematology & Oncology · Miami, FL
- Karthik V. Giridhar, MD Medical Oncology · Rochester, MN
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Mayo Clinic $360,108
- University of Miami Hosp & Clinics $224,944
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.